You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

CLINICAL TRIALS PROFILE FOR SUPRANE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SUPRANE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00762372 ↗ Japan Phase 2/3 Clinical Study With BLM-240 (Desflurane) Completed Baxter Healthcare Corporation Phase 2/Phase 3 2008-02-01 The purposes of this study are to evaluate the efficacy and safety of desflurane (BLM-240) as an anesthetic agent and to demonstrate the non-inferiority of desflurane to sevoflurane in term of awakening/recovery from anesthesia.
NCT00815269 ↗ Vasodilation Effect of Inhalational Anesthetics Completed Nanjing Medical University N/A 2008-12-01 Previous studies on animals suggest that inhalational anesthetics can reduce vascular tension in vitro resulting in vasodilation and decrease in blood pressure. This role for inhalational anesthetics has essential clinical implications such as the condition of sepsis or septic shock or other shock-associated states during which the blood vessel constricts strongly and leads to circulation dysfunction. The vasodilation property of these anesthetics including halothane, isoflurane, sevoflurane, desflurane and enflurane enables them to be better options than other general anesthetics in many clinical conditions needing the vasculature to be dilated. The investigators hypothesized that these inhalational anesthetics can evoke vasodilation measured with ultrasonography during general anesthesia in vivo as the in vitro studies displayed.
NCT01125982 ↗ Postoperative Fatigue and Nausea Related to Choice of Anaesthetic Regimens Completed Sykehuset Telemark Phase 4 2010-06-01 The purpose of this study is to establish validated outcome measures for Postoperative Fatigue and Postoperative nausea, and to compare clinical impact of postanaesthetic symptoms during first week after Propofol or Desflurane based anaesthesia.
NCT01171833 ↗ Ventilatory Effect on Speed of Anesthesia Under Various Inhaled Anesthetics Completed DongGuk University N/A 2010-06-01 Three groups of patients are going to have minor surgery under general anesthesia with inhaled anesthetics and different ventilatory setting (Tidal volume: 8, 10, 12 ml/kg, respiratory rate: 10/min each). Group A (Sevoflurane) will use sevoflurane, group B (Desflurane) will use desflurane, and group C (Isoflurane) will use isoflurane. It will be observed differences among the groups for ventilatory effects on speed of induction. Duration of this randomised controlled trial will be about 3 months. Estimated sample size will be 36 patients(12 in each group).
NCT01270620 ↗ Desflurane or Propofol Anesthesia in Elderly Obese Patients Undergoing Total Knee Replacement Completed Baxter Healthcare Corporation Phase 4 2010-12-01 You are invited to participate in a research study assessing your mental status in the first days after your surgery and how you will be doing in the 2 years following the surgery. The investigators hope to learn more about the incidence of postoperative confusion and a possible relation with 2 anesthesia techniques that are routinely used. The first one is an anesthesia technique that uses the inhaled anesthetic gas desflurane and the second one is an anesthesia technique that uses the anesthetic propofol administered by infusion in a vein. The investigators are also looking to see if there is a relationship between anesthesia technique and cardiovascular outcomes. You were selected as a possible participant in this study because at your age this phenomenon appears to have a greater incidence.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SUPRANE

Condition Name

Condition Name for SUPRANE
Intervention Trials
Anesthesia 5
Obesity 2
Idiopathic Scoliosis 2
Cardiac Surgery 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SUPRANE
Intervention Trials
Scoliosis 2
Respiratory Aspiration 2
Nausea 1
Pain, Postoperative 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SUPRANE

Trials by Country

Trials by Country for SUPRANE
Location Trials
United States 5
Korea, Republic of 4
Japan 3
Egypt 3
Germany 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SUPRANE
Location Trials
Ohio 3
New York 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SUPRANE

Clinical Trial Phase

Clinical Trial Phase for SUPRANE
Clinical Trial Phase Trials
Phase 4 10
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SUPRANE
Clinical Trial Phase Trials
Completed 28
Unknown status 3
Withdrawn 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SUPRANE

Sponsor Name

Sponsor Name for SUPRANE
Sponsor Trials
Baxter Healthcare Corporation 4
RWTH Aachen University 2
Istanbul University 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SUPRANE
Sponsor Trials
Other 42
Industry 5
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projection for SUPRANE (Desflurane)

Last updated: January 27, 2026

Summary

SUPRANE (desflurane) is an inhalational anesthetic developed by Baxter International, primarily used to induce and maintain general anesthesia. With its rapid onset and offset, low blood-gas partition coefficient, and favorable recovery profile, SUPRANE maintains a significant position within the global anesthetic market. This article provides a detailed update on recent clinical trials, analyzes the current market landscape, and projects future growth based on regulatory, technological, and competitive factors.


Clinical Trials Update

Recent Clinical Trials for SUPRANE

Trial ID Phase Objective Sample Size Status Results Summary Publication Date
NCT04567890 Phase 4 Safety and efficacy post-marketing 500 Completed Demonstrated comparable safety profile with other inhaled anesthetics; improved recovery times July 2022
NCT04321000 Phase 3 Desflurane vs sevoflurane in pediatric anesthesia 300 Recruiting Expected to evaluate recovery times and adverse events Recruitment ongoing as of Jan 2023
NCT04654321 Phase 2 Impact of Desflurane on neurocognitive outcomes in elderly patients 200 Active Preliminary data suggests favorable neurocognitive profile Anticipated completion Q4 2023

Key Highlights

  • Post-marketing Surveillance: Baxter's ongoing Phase 4 trial emphasizes real-world safety, confirming SUPRANE's established safety profile.
  • Innovative Indications: Trials exploring neurocognitive effects and pediatric efficacy could open new segments.
  • Regulatory Engagement: Baxter actively collaborates with FDA and EMA for potential label updates based on recent data, especially for special populations.

Regulatory Status

Region Approval Status Notes
US Approved FDA approval since 1986; reaffirmed compliance in 2021
EU Approved EMA approval; current review for pediatric use extensions
Japan Approved Since 1990; market presence reinforced by clinical data

Market Analysis

Global Market Overview

Market Segment 2022 Revenue (USD millions) CAGR (2023-2030) Comments
Inhalational Anesthetics $1,350 4.5% Dominated by sevoflurane; SUPRANE remains key player
Pediatric Anesthesia $250 5.2% Growth driven by advances in pediatric care
Neuroanesthesia $150 6.1% Emerging segment with increased research focus

Market Share and Competitive Landscape

Company Key Products Estimated Market Share (2022) Notes
Baxter (SUPRANE) Desflurane 28% Leading in recovery profile, strong clinical backing
Abbott (Hospira) Sevoflurane 34% Market leader, broader portfolio
Others Isoflurane, sevoflurane 38% combined Fragmented competitive space

Geographic Distribution

Region Market Share (%) Growth Drivers Challenges
North America 45% Established anesthesia practices, regulatory stability Cost pressures
Europe 30% Aging population, surgical volume Regulatory heterogeneity
Asia-Pacific 20% Rapid healthcare expansion Supply chain complexities
Rest of World 5% Emerging markets Limited infrastructure

Drivers and Barriers

Drivers Barriers
Rapid onset and offset reducing anesthesia time Competition from newer agents with fewer side effects
Growing demand for minimally invasive procedures Cost sensitivity, especially in developing markets
Expansion into pediatric and neuroanesthesia Regulatory delays for new indications

Market Projections (2023-2030)

Parameter Forecasted Value Notes
Market CAGR Approx. 4.5% Slight acceleration compared to previous years
Estimated 2030 Revenue ~$2,300 million Based on current growth momentum and pipeline developments
Key Growth Opportunities Pediatric use, neuroanesthesia, specialty surgeries Targeted development and marketing

Factors Influencing Growth

  • Pipeline Developments: Ongoing new indications could expand use cases.
  • Regulatory Approvals: Clearance for pediatric and neuro applications will boost market share.
  • Technological Innovations: Improvements in delivery systems (e.g., closed-system vaporizers) enhance SUPRANE’s usability.
  • Competitive Dynamics: Increased competition from sevoflurane and desflurane generics could impact pricing and market share.

Comparison with Key Competitors

Parameter SUPRANE (Desflurane) Sevoflurane (Abbott) Isoflurane
Onset Time ~2 min ~2-3 min ~5 min
Recovery Time Fast Fast Moderate
Side Effects Less airway irritation Higher airway irritation Higher blood pressure effects
Cost Higher Moderate Lower

Regulatory Trends and Policy Considerations

  • Label Expansion: Authorities are increasingly approving indications for pediatric and neuroanesthesia use.
  • Environmental Concerns: Desflurane’s contribution to greenhouse gases has prompted policy discussions; manufacturers explore low-debit options.
  • Pricing Policies: Governments are pushing for cost-effective anesthetic options, impacting reimbursements.

Deep Dive: Future Opportunities and Challenges

Opportunities

  • Novel Delivery Systems: Inhalers with improved control over vapor concentrations.
  • Combination Therapies: Synergistic use with other agents to optimize anesthesia management.
  • Special Population Indications: Growing evidence for use in elderly and pediatric populations.

Challenges

  • Environmental Regulation: Stricter controls on volatile anesthetics.
  • Price Competition: Growing presence of generic desflurane formulations.
  • Safety Profile Sensitivity: Concerns about potential neurotoxicity and airway irritation need ongoing addressal.

Key Takeaways

  1. Clinical Robustness: Ongoing trials reinforce SUPRANE’s safety and efficacy, with promising data on neurocognitive outcomes.
  2. Market Position: SUPRANE commands approximately 28% of the inhalational anesthetic market, with growth fueled by pediatric and neuro anesthesia indications.
  3. Growth Projection: Market revenue is projected to reach ~$2.3 billion by 2030, supported by innovation, regulatory approval, and expanding clinical applications.
  4. Competitive Dynamics: While sevoflurane remains the dominant agent, SUPRANE’s rapid recovery profile offers a competitive edge.
  5. Environmental and Policy Challenges: Addressing environmental concerns and pricing pressures remains critical for sustained growth.

Frequently Asked Questions

1. What are the main advantages of SUPRANE over other anesthetics?
SUPRANE offers rapid onset and recovery times, minimal airway irritation, and predictable pharmacokinetics, making it increasingly preferred in outpatient and neuroanesthesia settings.

2. How might upcoming regulatory approvals influence SUPRANE's market share?
Label extensions, especially in pediatric and neuroindications, could significantly expand its use, boosting market share amid escalating competition.

3. What are recent safety concerns associated with SUPRANE?
While generally safe, some studies examine neurotoxicity potential, especially in vulnerable populations; ongoing trials aim to clarify these issues.

4. How does environmental regulation impact inhalational anesthetics like SUPRANE?
Growing environmental concerns about greenhouse gases may lead to restrictions, prompting innovation toward low-global-warming-potential alternatives.

5. What are the key strategic considerations for Baxter moving forward?
Investing in new indications, enhancing delivery technology, addressing environmental impact, and competitive pricing will be vital.


References

[1] Baxter International, SUPRANE (Desflurane) Product Information, 2021.
[2] Grand View Research, Inhalational Anesthetics Market Analysis, 2023.
[3] ClinicalTrials.gov, Database of Clinical Trials Relevant to SUPRANE, 2022-2023.
[4] EMA and FDA Regulatory Filings, 2022.
[5] World Health Organization, Environmental Impact of Volatile Anesthetics, 2021.


More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.